| Bioactivity | S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells[1]. |
| Target | IC50: 0.19 ± 0.08 μM (AKR1C3), 0.36 ± 0.15 μM (AKR1C4), 0.47 ± 0.16 μM (AKR1C1), 0.73 ± 0.35 μM (AKR1C2) |
| Invitro | S07-2010 (0-25 μM, 48h) exhibits obvious cytotoxicity on MCF-7/DOX and A549/DDP, with IC50 values of 127.5 and 5.51 μM, respectively[1]. |
| Name | S07-2010 |
| CAS | 1223194-71-5 |
| Formula | C19H21N3O3S |
| Molar Mass | 371.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Siyu He, et al. Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. ACS Med. Chem. Lett. 2022. |
S07-2010
CAS: 1223194-71-5 F: C19H21N3O3S W: 371.45
S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47,
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.